RH
Therapeutic Areas
EndLyz Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ATP13A2 Program | Genetic subsets of Parkinson's Disease | Pre-clinical |
| ATP10B Program | Genetic subsets of Parkinson's Disease (e.g., GBA1-associated) | Pre-clinical |
Leadership Team at EndLyz Therapeutics
JW
Joanna Wolak
CEO and co-founder
PV
Peter Vangheluwe
Scientific Co-founder
RW
Richard Wade-Martins
Scientific Co-founder
JD
John Davis
Scientific Co-founder
PF
Paul Fish
Head of Discovery
FL
Floriana Licitra
Associate Director, R&D
TE
Tim Edwards
Chairperson, Independent